Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 11;8(11):e36712.
doi: 10.2196/36712.

Outcomes of COVID-19 Infection in People Previously Vaccinated Against Influenza: Population-Based Cohort Study Using Primary Health Care Electronic Records

Affiliations

Outcomes of COVID-19 Infection in People Previously Vaccinated Against Influenza: Population-Based Cohort Study Using Primary Health Care Electronic Records

Maria Giner-Soriano et al. JMIR Public Health Surveill. .

Abstract

Background: A possible link between influenza immunization and susceptibility to the complications of COVID-19 infection has been previously suggested owing to a boost in the immunity against SARS-CoV-2.

Objective: This study aimed to investigate whether individuals with COVID-19 could have benefited from vaccination against influenza. We hypothesized that the immunity resulting from the previous influenza vaccination would boost part of the immunity against SARS-CoV-2.

Methods: We performed a population-based cohort study including all patients with COVID-19 with registered entries in the primary health care (PHC) electronic records during the first wave of the COVID-19 pandemic (March 1 to June 30, 2020) in Catalonia, Spain. We compared individuals who took an influenza vaccine before being infected with COVID-19, with those who had not taken one. Data were obtained from Information System for Research in Primary Care, capturing PHC information of 5.8 million people from Catalonia. The main outcomes assessed during follow-up were a diagnosis of pneumonia, hospital admission, and mortality.

Results: We included 309,039 individuals with COVID-19 and compared them on the basis of their influenza immunization status, with 114,181 (36.9%) having been vaccinated at least once and 194,858 (63.1%) having never been vaccinated. In total, 21,721 (19%) vaccinated individuals and 11,000 (5.7%) unvaccinated individuals had at least one of their outcomes assessed. Those vaccinated against influenza at any time (odds ratio [OR] 1.14, 95% CI 1.10-1.19), recently (OR 1.13, 95% CI 1.10-1.18), or recurrently (OR 1.10, 95% CI 1.05-1.15) before being infected with COVID-19 had a higher risk of presenting at least one of the outcomes than did unvaccinated individuals. When we excluded people living in long-term care facilities, the results were similar.

Conclusions: We could not establish a protective role of the immunity conferred by the influenza vaccine on the outcomes of COVID-19 infection, as the risk of COVID-19 complications was higher in vaccinated than in unvaccinated individuals. Our results correspond to the first wave of the COVID-19 pandemic, where more complications and mortalities due to COVID-19 had occurred. Despite that, our study adds more evidence for the analysis of a possible link between the quality of immunity and COVID-19 outcomes, particularly in the PHC setting.

Keywords: COVID-19; SARS-CoV-2; cohort study; eHeatlh; electronic health records; epidemiology; health outcome; influenza vaccines; mortality; pneumonia; primary health care; public health; vaccination.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Risk of death and of combined COVID-19 complications in all the vaccinated population and excluding people living in long-term care facilities (LTCF).

Similar articles

Cited by

References

    1. Coronavirus disease 2019 (‎COVID-19)‎: situation report, 51. World Health Organization. 2020. [2022-10-31]. https://apps.who.int/iris/handle/10665/331475 .
    1. Ioannidis JPA. Reconciling estimates of global spread and infection fatality rates of COVID-19: an overview of systematic evaluations. Eur J Clin Invest. 2021 May;51(5):e13554. doi: 10.1111/eci.13554. https://europepmc.org/abstract/MED/33768536 - DOI - PMC - PubMed
    1. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022 Jan 05;23(1):3–20. doi: 10.1038/s41580-021-00418-x. https://europepmc.org/abstract/MED/34611326 10.1038/s41580-021-00418-x - DOI - PMC - PubMed
    1. Boehm E, Kronig I, Neher R, Eckerle I, Vetter P, Kaiser L, Geneva Centre for Emerging Viral Diseases Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021 Aug;27(8):1109–1117. doi: 10.1016/j.cmi.2021.05.022. https://linkinghub.elsevier.com/retrieve/pii/S1198-743X(21)00262-7 S1198-743X(21)00262-7 - DOI - PMC - PubMed
    1. Manzanares-Meza LD, Medina-Contreras O. SARS-CoV-2 and influenza: a comparative overview and treatment implications. Bol Med Hosp Infant Mex. 2020;77(5):262–273. doi: 10.24875/BMHIM.20000183. http://www.bmhim.com/frame_esp.php?id=177 j77/5/262 - DOI - PubMed

Substances